

# **WG Considerations; Updates to the 2018-19 Recommendations**

Lisa Grohskopf, MD, MPH

Influenza Division, CDC

Advisory Committee on Immunization Practices

June 20, 2018

# Acknowledgments

## **Influenza Division**

Noreen Alabi  
Lenee Blanton  
Lynnette Brammer  
Joe Bresee  
Alicia Budd  
Jessie Chung  
Jill Ferdinands  
Brendan Flannery  
Alicia Fry  
Dan Jernigan  
Jackie Katz  
Krista Kniss  
Natalie Kramer  
Desiree Mustaquim  
Sonja Olsen  
Leslie Sokolow  
Calli Taylor  
Jerry Tokars  
Tim Uyeki

## **Immunization Safety Office**

Karen Broder  
Frank Destefano  
Penina Haber  
Tom Shimabukuro

## **Immunization Services Division**

Sam Graitcer  
Andrew Kroger  
Amy Parker Fiebelkorn  
Jeanne Santoli

# WG Considerations and Ongoing Discussions

- Considerations
  - 2017-18 season safety data reassuring
  - Discussion regarding quadrivalent adjuvanted vaccine for young children:
    - Reactogenicity
    - Very limited data on coadministration with other vaccines
- Ongoing discussions
  - Vaccine efficacy/effectiveness
    - LAIV4
    - Egg-based vs. non egg-based vaccines
    - Vaccines for persons aged 65 years and older
  - Surveillance, safety and vaccine coverage updates

## 2018-19 ACIP Influenza Recommendations— Core Recommendation:

- Re-iterates core recommendation that annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications.

# 2018-19 ACIP Influenza Recommendations—Updates: Vaccine Composition for 2018-19

- U.S. Influenza vaccine composition for 2018-19
  - Trivalent Vaccines
    - A/Michigan/45/2015 (H1N1)pdm09-like virus
    - A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus--updated
    - B/Colorado/06/2017-like virus (Victoria lineage)--updated
  - Quadrivalent Vaccines
    - Above three, plus B/Phuket/3073/2013-like virus (Yamagata lineage)

# 2018-19 ACIP Influenza Recommendations—Updates: FluMist Quadrivalent (LAIV4)

- New language approved by ACIP at vote in February 2018
  - For the 2018-19 season, providers may choose to administer any licensed, age-appropriate influenza vaccine (IIV, RIV4, or LAIV4). LAIV4 is an option for those for whom it is otherwise appropriate.
- Updated VE estimates for LAIV4 will be presented as they become available
- Contraindications and precautions remain the same as previously
- LAIV4 is acceptable for persons with a history of egg allergy (approved by ACIP in February 2016, prior to the decision to not recommend use of LAIV4 for 2016-2017)

# 2018-19 ACIP Influenza Recommendations—Updates: New Products/Licensure Changes

- Fluarix Quadrivalent (IIV4, GSK)
  - 0.5mL dose licensed for children aged  $\geq 6$  months (previously licensed for  $\geq 3$  years) in January 2018
  - Data presented to ACIP in February 2018
  - Three inactivated influenza vaccines licensed for 6- through 35-month-olds:
    - Fluarix Quadrivalent (IIV4, GSK)—0.5mL dose
    - FluLaval Quadrivalent (IIV4, GSK)—0.5mL dose
    - Fluzone Quadrivalent (IIV4, Sanofi Pasteur)—0.25mL dose

## **2018-19 Influenza Recommendations Discussion and Vote:**

Reaffirm the seasonal influenza recommendations for the  
2018-2019 season



For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.